A 6 Month, Phase II Randomized, Double-Blind, Placebo Controlled, Flexible Dosing, Crossover Trial of Atomoxetine in Subjects With Mild Cognitive Impairment.
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Atomoxetine (Primary)
- Indications Mild cognitive impairment
- Focus Adverse reactions; Biomarker; Pharmacodynamics; Proof of concept
- 11 Jul 2018 Status changed from active, no longer recruiting to completed.
- 06 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 13 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Sep 2017.